<DOC>
	<DOCNO>NCT02975453</DOCNO>
	<brief_summary>Evaluation performance 2MACE index population nonvalvular atrial fibrillation ( NVAF ) patient treated rivaroxaban Spain</brief_summary>
	<brief_title>Study Major Cardiovascular Events Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Adult patient age 18 year old . Patients diagnosis NVAF . Patients treated rivaroxaban least six month prior study inclusion . Patients give appropriate information study objectives procedure give write informed consent . Patients participate investigational program intervention outside routine clinical practice . Patients initiate treatment rivaroxaban start study inclusion period . Prosthetic heart valve presence severe valvulopathies . Patients severe cognitive impairment . Patients chronic infection ( HIV infection , hepatitis C virus , hepatitis B virus ) systemic autoimmune disease . Patients active cancer . Patients liver insufficiency ( eg . cirrhosis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>